Life Science Investing Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Life Science Investing Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Life Science Investing Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Life Science Investing Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Life Science Investing Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
Life Science Investing Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635
Life Science Investing Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
Placement to Institutional and Sophisticated Investors, Appointment of Joint Broker,Issue of Equity & TVR
